Multiple mRNA Vaccines Prepare to Tackle Other Diseases

Massachusetts-based Moderna, Inc., a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, recently reported financial results and provided business updates for the second quarter of the fiscal year 2022.

In addition to the impressive financial results announced on August 3, 2022, Moderna disclosed its progress in developing mRNA vaccines for other diseases.

Moderna's non-COVID-19 vaccine candidates included, but are not limited to, the following candidates:

• Phase 3 safety and immunogenicity trial started in June in the Southern Hemisphere for seasonal flu vaccine candidate (mRNA-1010) to support potential accelerated approval. In addition, the company is preparing for a Phase 3 efficacy study in fall 2022 (if needed); Flu (mRNA-1020/-30) Phase 1/2 trial fully enrolled.
• Combination COVID + flu (mRNA-1073) Phase 1/2 fully enrolled; combination COVID + flu + RSV (mRNA-1230) in preclinical studies, expected to start Phase 1 trial later this year; endemic human coronavirus (mRNA-1287) in preclinical
• Pediatric hMPV + PIV3 (mRNA-1653) Phase 1b fully enrolled; pediatric RSV + hMPV (mRNA-1365) in preclinical
• Older adults RSV Phase 3 (mRNA-1345), known as ConquerRSV, is ongoing; pediatric RSV in Phase 1
• CMV vaccine (mRNA-1647) pivotal Phase 3 study, known as CMVictory, is ongoing
• EBV vaccine (to prevent infectious mononucleosis) (mRNA-1189) Phase 1 is ongoing; EBV vaccine (to prevent EBV sequelae) (mRNA-1195) in preclinical studies
• HIV vaccines (mRNA-1644 and mRNA-1574) Phase 1 trials are ongoing
• HSV vaccine (mRNA-1608) and VZV vaccine (mRNA-1468) in preclinical studies
• Zika vaccine (mRNA-1893) is ongoing in a Phase 2 study
• Nipah vaccine (mRNA-1215) Phase 1 study, led by the U.S. NIH, is ongoing (the first participant dosed in July).

Stéphane Bancel, Moderna's CEO, stated in a press release, "Despite the slowing economy and challenges in the biotech industry, Moderna is in a unique position: a platform to drive scale and speed in research of new medicines, a strong balance sheet with $18 billion of cash and an agile, mission-driven team of over 3,400 people and growing."

"We will continue to invest and grow as we have never been as optimistic about Moderna's future."

"Right now, we have four infectious disease vaccines in Phase 3 trials, and later this year, we expect important data from proof-of-concept studies in rare diseases and immuno-oncology."

"Our teams are actively working to prepare these new product launches to help patients and drive growth."

"This is an exciting time for Moderna as we continue to see significant scientific and business momentum."

Note: Moderna's press release was manually curated for mobile readers.